Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study of Olaparib and Durvalumab for Patients with Metastatic Pancreatic Cancer and DNA Repair Gene Alterations

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of two medications, olaparib and durvalumab (also known as MEDI4736), in patients with metastatic pancreatic cancer. Metastatic pancreatic cancer is a type of cancer that has spread from the pancreas to other parts of the body. The study aims to evaluate how well these medications work together in treating this condition, particularly in patients who have specific changes in their DNA that affect how their cells repair damage.

Participants in the study will receive a combination of olaparib and durvalumab. Olaparib is taken orally, meaning it is swallowed in pill form, while durvalumab is given through an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. The study will last for a period of up to six months, during which the effects of the treatment will be monitored. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

The purpose of the study is to assess the overall response rate, which refers to the percentage of patients who experience a reduction in the size of their tumors or complete disappearance of the cancer. The study will also look at other outcomes, such as the time it takes for the disease to progress and the overall survival of the participants. This research is important for understanding how these medications can be used to improve treatment for patients with metastatic pancreatic cancer and specific DNA changes.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the clinical trial, an initial visit is scheduled. During this visit, eligibility is confirmed based on specific criteria, including age, previous treatments, and overall health status.

    A series of tests and assessments are conducted to ensure normal organ and bone marrow function. A performance status score is evaluated to determine the ability to perform daily activities.

  2. Step 2

    Consent and preparation

    Written informed consent is obtained, confirming understanding and agreement to comply with the trial requirements.

    For women of childbearing potential, a pregnancy test is conducted. Male participants are advised on contraceptive measures during and after the trial.

  3. Step 3

    Treatment initiation

    The treatment phase begins with the administration of two medications: durvalumab and olaparib.

    Durvalumab is given through an intravenous infusion, which involves receiving the medication directly into the bloodstream through a vein.

    Olaparib is taken orally in the form of tablets. The dosage and frequency are determined by the medical team based on individual needs.

  4. Step 4

    Ongoing treatment and monitoring

    Regular visits are scheduled to monitor the response to treatment and manage any side effects. These visits include physical examinations, blood tests, and imaging studies.

    The overall response rate is assessed to determine the effectiveness of the treatment. Adjustments to the treatment plan may be made based on these assessments.

  5. Step 5

    End of treatment

    The treatment phase continues until the study's end date or until it is determined that the treatment is no longer beneficial.

    A final assessment is conducted to evaluate the overall health status and response to the treatment.

Who can join the trial?

15 criteria

  • Must be a male or female aged 18 years or older.
  • Must have received platinum-based chemotherapy and benefited from it without the disease getting worse during treatment. Benefit means the disease got smaller or stayed the same for at least 6 months.
  • Must have normal organ and bone marrow function, which will be checked within 28 days before starting the study treatment.
  • Must weigh more than 30 kg (about 66 pounds).
  • Must have a Performance Status score of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG) scale, which measures how well you can perform daily activities.
  • Must have a measurable disease as defined by specific guidelines (RECIST version 1.1).
  • Must have a life expectancy of at least 16 weeks.
  • Women who can have children must show they are not pregnant with a negative pregnancy test within 7 days before starting the study treatment.
  • Male patients must use a condom during treatment and for 3 months after the last dose when having sexual intercourse with a pregnant woman or a woman who can have children. Female partners should also use a highly effective form of birth control if they can have children. Male patients should not donate sperm during treatment and for 3 months after the last dose.
  • Must have recovered from any side effects of previous treatments to a mild level, except for hair loss.
  • Must be willing and able to attend scheduled visits, follow the treatment plan, and undergo laboratory tests and other trial procedures.
  • Must provide written informed consent, which means agreeing to participate in the study after understanding all the details.
  • Must have a confirmed diagnosis of metastatic adenocarcinoma of the pancreas, which means the cancer has spread from the pancreas to other parts of the body.
  • Must have changes in DNA damage repair (DDR) genes in the tumor tissue or blood, which will be tested by a laboratory.
  • Must have received at least one line of chemotherapy for metastatic disease and no more than two lines. If the disease came back within 6 months after completing previous treatment, it counts as the first line of chemotherapy.

Who cannot join the trial?

8 criteria

  • Patients who have a different type of cancer than metastatic pancreatic cancer cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not able to provide informed consent cannot participate.
  • Patients who have any other serious medical conditions that might interfere with the study cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have had another cancer treatment recently that might interfere with the study cannot participate.
  • Patients who have allergies to the study medications cannot participate.
  • Patients who are participating in another clinical trial cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Olaparib

    is a medication used in this clinical trial to help treat patients with metastatic pancreatic cancer. It works by targeting cancer cells that have specific genetic changes, particularly in DNA Damage Repair genes. By interfering with the cancer cells' ability to repair their DNA, olaparib can help slow down or stop the growth of the cancer.

  • Durvalumab

    , also known by its code name MEDI4736, is another medication used in this trial. It is an immunotherapy drug that helps the body's immune system recognize and attack cancer cells. Durvalumab works by blocking a specific protein that cancer cells use to hide from the immune system, allowing the immune system to better detect and destroy the cancer cells.

What is already known about the treatment

  • Olaparib

    Olaparib is taken orally in the form of tablets and is currently being studied for its effectiveness in treating metastatic pancreatic cancer, especially in patients with specific genetic changes related to DNA repair. It works by blocking a protein called PARP, which helps repair damaged DNA in cells, and by doing so, it can prevent cancer cells from repairing themselves, leading to their death. Olaparib is classified as a PARP inhibitor and is primarily used in cancer treatments where DNA repair is a factor.

  • Durvalumab

    Durvalumab is administered through an intravenous infusion and is being investigated for its potential to treat metastatic pancreatic cancer in combination with olaparib. It functions by targeting a protein called PD-L1, which is used by cancer cells to hide from the immune system, and by blocking this protein, durvalumab helps the immune system recognize and attack cancer cells. Durvalumab is classified as an immune checkpoint inhibitor and is used to enhance the body's immune response against cancer.

Investigated diseases

Metastatic pancreatic cancer – This disease occurs when cancer that originated in the pancreas spreads to other parts of the body. It typically progresses through the lymphatic system or bloodstream, reaching organs such as the liver, lungs, or peritoneum. As the cancer spreads, it can cause symptoms like abdominal pain, weight loss, and jaundice. The progression often involves the formation of new tumors in the affected organs, which can disrupt their normal function. Over time, the disease can lead to increased complications as more organs become involved. The spread of cancer cells can also lead to the development of secondary tumors, further complicating the condition.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-510970-26-00Protocol codeTTD-20-04Estimated enrolment40 patientsSponsorAsociacion Grupo Tratamiento De Tumores Digestivos

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.